17022-31-0

Basic information

• Product Name: ETHYL 2-PROPYLPENTANOATE
• Synonyms: ETHYL 2-PROPYLPENTANOATE;valproic acid ethyl ester;Ethyl dipropylacetate;Ethyl valproate;Pentanoic acid, 2-propyl-, ethyl ester
• CAS NO: 17022-31-0
• Molecular Formula: C₁₀H₂₀O₂
• Molecular Weight: 172.26
• Mol File: 17022-31-0.mol

Chemical Properties

• Boiling Point: 195.7°Cat760mmHg
• Flash Point: 71.4°C
• Appearance: /
• Density: 0.872g/cm³
• Vapor Pressure: 0.413mmHg at 25°C
• Refractive Index: 1.421
• Storage Temp.: Refrigerator
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• CAS DataBase Reference: ETHYL 2-PROPYLPENTANOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-PROPYLPENTANOATE(17022-31-0)
• EPA Substance Registry System: ETHYL 2-PROPYLPENTANOATE(17022-31-0)

Safety Data

• Hazardous Substances Data: 17022-31-0(Hazardous Substances Data)

Usage

Uses

Used in Biofuel Industry:
ETHYL 2-PROPYLPENTANOATE is used as a potential biofuel due to its properties that make it suitable for use as an alternative energy source.
Used in Fragrance Industry:
ETHYL 2-PROPYLPENTANOATE is used as a fragrance ingredient for its pleasant odor, making it suitable for use in various scented products.
Used in Pharmaceutical Industry:
ETHYL 2-PROPYLPENTANOATE is used as an intermediate in the synthesis of antiepileptic drugs, specifically Valproic Acid, which is used for the treatment of various neurological disorders.

InChI:InChI=1/C10H20O2/c1-4-7-9(8-5-2)10(11)12-6-3/h9H,4-8H2,1-3H3

Upstream product

• 64-17-5 ethanol 
• 99-66-1 valproic acid 
• 6065-63-0 2,2-dipropyl-malonic acid diethyl ester 
• 60-29-7 diethyl ether 
• 539-82-2 ethyl n-valerate 
• 106-94-5 propyl bromide 
• 76002-02-3 ethyl 2-acetyl-2-propylpentanoate 
• 2936-08-5 valproyl chloride 

Downstream Products

• 1069-66-5 sodium valproate 
• 690988-44-4 ethyl 4-(2-propylpentanamido)benzoate 
• 2936-08-5 valproyl chloride 
• 130201-25-1 1,1-Bis(4'-brombiphenyl-3-yl)-2-propyl-1-penten 
• 130201-23-9 1,1-Bis(4'-brombiphenyl-3-yl)-2-propyl-1-pentanol 
• 99-66-1 valproic acid 

Relevant articles and documents

Enantio- and Regioselective Palladium(II)-Catalyzed Dioxygenation of (Aza-)Alkenols

An oxidative Pd-catalyzed intra-intermolecular dioxygenation of (aza-)alkenols has been reported, with total regioselectivity. To study the stereoselectivity, different chiral ligands as well as different hypervalent-iodine compounds have been compared. I

Preparation method of sodium valproate

The invention provides a preparation method of sodium valproate, and belongs to the technical field of medicine synthesis. The method comprises the following steps: by taking ethyl valerate as a raw material, adding a methyl tert-butyl ether solution of a pyrrole metal reagent into an ether solution of ethyl valerate, then adding halopropane, carrying out an alkylation reaction, adding a weakly acidic solution in a dropwise manner to terminate the reaction after the reaction is finished, and washing with water to obtain an intermediate product; and adding a sodium hydroxide solution into the alcohol solvent of the intermediate product, carrying out a saponification reaction, and purifying to obtain sodium valproate after the saponification reaction is finished. The method is short in reaction route, high in total yield, easily available in raw materials, low in cost, high in operability and suitable for industrialization. The total molar yield of sodium valproate prepared by the methodis greater than or equal to 86.0%, and the purity of the final product is greater than or equal to 99.5%.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, migraine, schizophrenia, depression, Alzheimer's disease, cancer, HIV and familial adenomatous polyposis.